Authors: A. Jurečková; I. Kocáková; R. Vyzula Authors‘ workplace: Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno Published in: Klin Onkol 2012; 25(2): 135-138 Category: Reports from Clinical Registries
1. Demetri GD, Benjamin R, Blanke CD et al. NCCN Task Force Report : Optimal management of patients with gastrointestinal stromal tumor (GIST). Expansion and Update of NCCN Clinical Practice Guidelines. J Natl Compr Canc Netw 2004; 2: S1–S26.
2. Demetri G, van Oosterom A, Garrett C et al. Improved survival and sustained clinical benefit with SU11248 (SU) in pts with GIST after failure of imatinib mesylate (IM) therapy in a phase III trial. Gastrointestinal Cancers Symposium 2006.
3. Casali PG, Garrett CR, Blackstein ME et al. Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Clin Oncol 2006; 24(18 Suppl): 9513.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
